Preparation, Characterization, and Preliminary Imaging Study of [<sup>188</sup>Re]Re-Ibandronate as a Novel Theranostic Radiopharmaceutical for Bone Metastasis

<table class="table-group" id="tab5"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td class="align_left">ROI ratio</td><td class="align_center">6 h</td><td class="align_center">16 h</td><td class="align_center">32 h</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td class="align_left">Mean</td><td class="align_center">1.245</td><td class="align_center">1.633</td><td class="align_center">1.529</td></tr><tr><td class="align_left">SD</td><td class="align_center">0.295</td><td class="align_center">0.472</td><td class="align_center">0.187</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>ROI ratio of model bone/contralateral bone in nude mice of bone metastasis model (<i>n</i> = 4).</div>

Contrast Media & Molecular Imaging

tab5

Table 5

Table 5: Preparation, Characterization, and Preliminary Imaging Study of [<sup>188</sup>Re]Re-Ibandronate as a Novel Theranostic Radiopharmaceutical for Bone Metastasis 

Table 5 | Preparation, Characterization, and Preliminary Imaging Study of [188Re]Re-Ibandronate as a Novel Theranostic Radiopharmaceutical for Bone Metastasis 